Results 211 to 220 of about 24,853 (244)

Ruxolitinib

Reactions Weekly, 2023
  +6 more sources

Ruxolitinib

Reactions Weekly, 2022
  +6 more sources

The impact of starting dose on overall survival in myelofibrosis patients treated with ruxolitinib: A prospective real‐world study on AIFA monitoring registries

British Journal of Haematology
Ruxolitinib is a JAK1/JAK2 inhibitor approved for the treatment of myelofibrosis (MF)‐related splenomegaly or symptoms. The recommended starting dose depends on platelet count, regardless of haemoglobin level at baseline.
M. Breccia, Simone Celant, F. Palandri, F. Passamonti, P. Olimpieri, V. Summa, Annalisa Guarcello, G. Palumbo, Fabrizio Pane, P. Guglielmelli, P. Corradini, Pierluigi Russo   +11 more
semanticscholar   +1 more source

Ruxolitinib attenuates microglial inflammatory response by inhibiting NF-κB/MAPK signaling pathway.

European Journal of Pharmacology
Neuroinflammation is involved in the physiological and pathological processes of numerous neurological diseases, and its inhibition seems to be a promising therapeutic direction for these diseases.
Jingli Min, Hongmei Zheng, Heye Xia, Xuejun Tian, Meihao Liang, Jing Zhang, Wenhai Huang   +6 more
semanticscholar   +1 more source

Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial.

The Lancet Haematology
BACKGROUND Most patients with myelofibrosis develop ruxolitinib intolerance or disease that is relapsed or refractory, and survival rates after ruxolitinib discontinuation are poor.
Claire N. Harrison, R. Mesa, Moshe Talpaz, H. Al-Ali, Blanca Xicoy, F. Passamonti, F. Palandri, G. Benevolo, A. Vannucchi, Clémence Médiavilla, A. Iurlo, Inho Kim, S. Rose, Patrick A. Brown, C. Hernandez, Jia Wang, J. Kiladjian   +16 more
semanticscholar   +1 more source

Ruxolitinib

Reactions Weekly, 2019
  +8 more sources

Ruxolitinib

Reactions Weekly, 2021
  +5 more sources

Combination ruxolitinib and belumosudil is tolerable and induces responses despite treatment failure as monotherapies

Leukemia and Lymphoma
FDA approved agents for the treatment of chronic GVHD including ruxolitinib and belumosudil are effective steroid-sparing agents, with overall response rates (ORR) of 76% and 65% respectively. Ruxolitinib and belumosudil are well tolerated with different
Jean Caputo, Ayush Peddireddi, Subodh Bhatta, Ying Huang, Evandro D Bezerra, J. Brammer, K. Larkin, Alice Mims, S. Vasu, Sarah A. Wall, Hannah Choe   +10 more
semanticscholar   +1 more source

Ruxolitinib

Reactions Weekly, 2017
  +6 more sources

Addition of navitoclax to ruxolitinib for patients with myelofibrosis with progression or suboptimal response

Blood neoplasia
Key Points • Adding navitoclax to ongoing ruxolitinib demonstrates durable responses and potential disease modification in relapsed/refractory MF.• Thrombocytopenia is the most common adverse event and is manageable and reversible with dose reduction as ...
N. Pemmaraju, T. Somervaille, F. Palandri, Claire N. Harrison, R. Komrokji, A. Perkins, R. Ayala Diaz, D. Lavie, Akihiro Tomita, Yang Feng, Q. Qin, Jason Harb, Akshanth R. Polepally, J. Potluri, Jacqueline S. Garcia   +14 more
semanticscholar   +1 more source